Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

Cristiana Montemagni,1,2 Tiziana Frieri,1,2 Paola Rocca1,2 1Department of Neuroscience, Unit of Psychiatry, University of Turin, 2Department of Mental Health, Azienda Sanitaria Locale (ASL) Torino 1 (TO1), Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Tori...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Montemagni C, Frieri T, Rocca P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	long-acting injectable antipsychotics second-generation antipsychotics quality of life schizophrenia functioning Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0df15e1f5c4d4621afaf1e7cf75c316f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0df15e1f5c4d4621afaf1e7cf75c316f
record_format	dspace
spelling	oai:doaj.org-article:0df15e1f5c4d4621afaf1e7cf75c316f2021-12-02T08:20:58ZSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life1178-2021https://doaj.org/article/0df15e1f5c4d4621afaf1e7cf75c316f2016-04-01T00:00:00Zhttps://www.dovepress.com/second-generation-long-acting-injectable-antipsychotics-in-schizophren-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Cristiana Montemagni,1,2 Tiziana Frieri,1,2 Paola Rocca1,2 1Department of Neuroscience, Unit of Psychiatry, University of Turin, 2Department of Mental Health, Azienda Sanitaria Locale (ASL) Torino 1 (TO1), Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy Abstract: Long-acting injectable antipsychotics (LAIs) were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-generation antipsychotic LAIs (SGA-LAIs) combine the advantages of SGA with a long-acting formulation. The purpose of this review is to evaluate the available literature concerning the impact of SGA-LAIs on patient functioning and quality of life (QOL). Although several studies regarding schizophrenia patients’ functioning and QOL have been performed, the quantity of available data still varies greatly depending on the SGA-LAI under investigation. After reviewing the literature, it seems that SGA-LAIs are effective in ameliorating patient functioning and/or QOL of patients with schizophrenia, as compared with placebo. However, while methodological design controversy exists regarding the superiority of risperidone LAI versus oral antipsychotics, the significant amount of evidence in recently published research demonstrates the beneficial influence of risperidone LAI on patient functioning and QOL in stable patients and no benefit over oral treatment in unstable patients. However, the status of the research on SGA-LAIs is lacking in several aspects that may help physicians in choosing the correct drug therapy. Meaningful differences have been observed between SGA-LAIs in the onset of their clinical efficacy and in the relationships between symptoms and functioning scores. Moreover, head-to-head studies comparing the effects of SGA-LAIs on classical measures of psychopathology and functioning are available mainly on risperidone LAI, while those comparing olanzapine LAI with other SGA-LAIs are still lacking. Lastly, some data on their use, especially in first-episode or recent-onset schizophrenia and in refractory or treatment-resistant schizophrenia, is available. Keywords: outcome, first-episode schizophrenia, recent-onset schizophrenia, treatment resistant schizophreniaMontemagni CFrieri TRocca PDove Medical Pressarticlelong-acting injectable antipsychoticssecond-generation antipsychoticsquality of lifeschizophreniafunctioningNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 917-929 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	long-acting injectable antipsychotics second-generation antipsychotics quality of life schizophrenia functioning Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	long-acting injectable antipsychotics second-generation antipsychotics quality of life schizophrenia functioning Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Montemagni C Frieri T Rocca P Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
description	Cristiana Montemagni,1,2 Tiziana Frieri,1,2 Paola Rocca1,2 1Department of Neuroscience, Unit of Psychiatry, University of Turin, 2Department of Mental Health, Azienda Sanitaria Locale (ASL) Torino 1 (TO1), Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy Abstract: Long-acting injectable antipsychotics (LAIs) were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-generation antipsychotic LAIs (SGA-LAIs) combine the advantages of SGA with a long-acting formulation. The purpose of this review is to evaluate the available literature concerning the impact of SGA-LAIs on patient functioning and quality of life (QOL). Although several studies regarding schizophrenia patients’ functioning and QOL have been performed, the quantity of available data still varies greatly depending on the SGA-LAI under investigation. After reviewing the literature, it seems that SGA-LAIs are effective in ameliorating patient functioning and/or QOL of patients with schizophrenia, as compared with placebo. However, while methodological design controversy exists regarding the superiority of risperidone LAI versus oral antipsychotics, the significant amount of evidence in recently published research demonstrates the beneficial influence of risperidone LAI on patient functioning and QOL in stable patients and no benefit over oral treatment in unstable patients. However, the status of the research on SGA-LAIs is lacking in several aspects that may help physicians in choosing the correct drug therapy. Meaningful differences have been observed between SGA-LAIs in the onset of their clinical efficacy and in the relationships between symptoms and functioning scores. Moreover, head-to-head studies comparing the effects of SGA-LAIs on classical measures of psychopathology and functioning are available mainly on risperidone LAI, while those comparing olanzapine LAI with other SGA-LAIs are still lacking. Lastly, some data on their use, especially in first-episode or recent-onset schizophrenia and in refractory or treatment-resistant schizophrenia, is available. Keywords: outcome, first-episode schizophrenia, recent-onset schizophrenia, treatment resistant schizophrenia
format	article
author	Montemagni C Frieri T Rocca P
author_facet	Montemagni C Frieri T Rocca P
author_sort	Montemagni C
title	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
title_short	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
title_full	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
title_fullStr	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
title_full_unstemmed	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
title_sort	second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/0df15e1f5c4d4621afaf1e7cf75c316f
work_keys_str_mv	AT montemagnic secondgenerationlongactinginjectableantipsychoticsinschizophreniapatientfunctioningandqualityoflife AT frierit secondgenerationlongactinginjectableantipsychoticsinschizophreniapatientfunctioningandqualityoflife AT roccap secondgenerationlongactinginjectableantipsychoticsinschizophreniapatientfunctioningandqualityoflife
_version_	1718398526526849024

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

Ejemplares similares